JP2014510735A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510735A5 JP2014510735A5 JP2014501409A JP2014501409A JP2014510735A5 JP 2014510735 A5 JP2014510735 A5 JP 2014510735A5 JP 2014501409 A JP2014501409 A JP 2014501409A JP 2014501409 A JP2014501409 A JP 2014501409A JP 2014510735 A5 JP2014510735 A5 JP 2014510735A5
- Authority
- JP
- Japan
- Prior art keywords
- lys
- glu
- gly
- ser
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 239000002994 raw material Substances 0.000 claims 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 2
- -1 9-fluorenyl-methoxycarbonyl Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110078314.X | 2011-03-30 | ||
| CN201110078314XA CN102718868A (zh) | 2011-03-30 | 2011-03-30 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
| PCT/CN2012/071910 WO2012130015A1 (zh) | 2011-03-30 | 2012-03-05 | 定点单取代聚乙二醇化Exendin类似物及其制备方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510735A JP2014510735A (ja) | 2014-05-01 |
| JP2014510735A5 true JP2014510735A5 (enExample) | 2015-04-23 |
| JP6297969B2 JP6297969B2 (ja) | 2018-03-20 |
Family
ID=46929417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501409A Active JP6297969B2 (ja) | 2011-03-30 | 2012-03-05 | 部位特異的モノｐｅｇ化エキセンジン類似体およびその調製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20140142037A1 (enExample) |
| EP (1) | EP2692730B1 (enExample) |
| JP (1) | JP6297969B2 (enExample) |
| KR (1) | KR102005385B1 (enExample) |
| CN (2) | CN106928341B (enExample) |
| AU (1) | AU2012237899B2 (enExample) |
| BR (1) | BR112013024706B1 (enExample) |
| CA (1) | CA2829122C (enExample) |
| RU (1) | RU2625015C2 (enExample) |
| WO (1) | WO2012130015A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| KR101768446B1 (ko) * | 2014-03-21 | 2017-08-17 | 애니젠 주식회사 | 신규한 엑세나타이드 유사체 및 그의 용도 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| GB201603510D0 (en) * | 2016-02-29 | 2016-04-13 | Univ Ulster | Compositions for use in the treatment of neurological disease |
| CN115703825A (zh) * | 2021-08-17 | 2023-02-17 | 派格生物医药(苏州)股份有限公司 | 艾塞那肽变体及其聚乙二醇缀合物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1162446C (zh) * | 2001-05-10 | 2004-08-18 | 上海华谊生物技术有限公司 | 促胰岛素分泌肽衍生物 |
| US7662915B2 (en) * | 2003-01-18 | 2010-02-16 | Pegsphere Co., Ltd. | Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated PEG peptides using the same |
| BRPI0407936A (pt) * | 2003-03-19 | 2006-02-21 | Lilly Co Eli | composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado |
| WO2006037811A2 (en) * | 2004-10-07 | 2006-04-13 | Novo Nordisk A/S | Protracted exendin-4 compounds |
| WO2007061148A1 (en) * | 2005-11-24 | 2007-05-31 | Pegsphere Co., Ltd. | Site-specific peg conjugates of glp-1 and methods for production thereof |
| KR100890989B1 (ko) * | 2006-06-01 | 2009-03-31 | 이강춘 | 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도 |
| CN102827284B (zh) * | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
| WO2008130066A1 (en) * | 2007-04-20 | 2008-10-30 | Kang Choon Lee | Mono modified exendin with polyethylene glycol or its derivatives and uses thereof |
| US7935877B2 (en) * | 2007-04-20 | 2011-05-03 | Master Key, Llc | System and method for music composition |
| AU2010225523B2 (en) * | 2009-03-20 | 2012-05-24 | Hanmi Science Co., Ltd. | Method for preparing a site-specific physiologically active polypeptide conjugate |
| CN101870728A (zh) * | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
| CN101559041B (zh) * | 2009-05-19 | 2014-01-15 | 中国科学院过程工程研究所 | 粒径均一的多肽药物缓释微球或微囊制剂及制备方法 |
| BR112012007374A2 (pt) * | 2009-09-30 | 2019-09-24 | Glaxo Group Ltd | composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante |
| CN102397558B (zh) * | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
-
2011
- 2011-03-30 CN CN201710091006.8A patent/CN106928341B/zh active Active
- 2011-03-30 CN CN201110078314XA patent/CN102718868A/zh active Pending
-
2012
- 2012-03-05 WO PCT/CN2012/071910 patent/WO2012130015A1/zh not_active Ceased
- 2012-03-05 JP JP2014501409A patent/JP6297969B2/ja active Active
- 2012-03-05 CA CA2829122A patent/CA2829122C/en active Active
- 2012-03-05 EP EP12765410.1A patent/EP2692730B1/en active Active
- 2012-03-05 KR KR1020137028242A patent/KR102005385B1/ko active Active
- 2012-03-05 RU RU2013147468A patent/RU2625015C2/ru active
- 2012-03-05 AU AU2012237899A patent/AU2012237899B2/en active Active
- 2012-03-05 BR BR112013024706-1A patent/BR112013024706B1/pt active IP Right Grant
-
2013
- 2013-09-30 US US14/042,544 patent/US20140142037A1/en not_active Abandoned